JP5401457B2 - 抗菌ペプチド、組成物及びその使用方法 - Google Patents
抗菌ペプチド、組成物及びその使用方法 Download PDFInfo
- Publication number
- JP5401457B2 JP5401457B2 JP2010518431A JP2010518431A JP5401457B2 JP 5401457 B2 JP5401457 B2 JP 5401457B2 JP 2010518431 A JP2010518431 A JP 2010518431A JP 2010518431 A JP2010518431 A JP 2010518431A JP 5401457 B2 JP5401457 B2 JP 5401457B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- arg
- present
- peptide
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 93
- 239000003910 polypeptide antibiotic agent Substances 0.000 title description 22
- 238000000034 method Methods 0.000 title description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 51
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 125000002091 cationic group Chemical group 0.000 claims description 11
- 239000006071 cream Substances 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- 239000007922 nasal spray Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 229940097496 nasal spray Drugs 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000008247 solid mixture Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 25
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 18
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 18
- 208000015181 infectious disease Diseases 0.000 description 18
- 238000009472 formulation Methods 0.000 description 16
- 230000002265 prevention Effects 0.000 description 16
- 208000035143 Bacterial infection Diseases 0.000 description 15
- 208000022362 bacterial infectious disease Diseases 0.000 description 15
- -1 penetrants Substances 0.000 description 13
- 208000002874 Acne Vulgaris Diseases 0.000 description 11
- 206010000496 acne Diseases 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 10
- 230000007774 longterm Effects 0.000 description 10
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 210000000282 nail Anatomy 0.000 description 9
- 108030001720 Bontoxilysin Proteins 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 206010017533 Fungal infection Diseases 0.000 description 6
- 208000010195 Onychomycosis Diseases 0.000 description 6
- 229940053031 botulinum toxin Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 201000005882 tinea unguium Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 5
- 208000031888 Mycoses Diseases 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 229960000541 cetyl alcohol Drugs 0.000 description 5
- 208000002925 dental caries Diseases 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 239000002324 mouth wash Substances 0.000 description 5
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- 206010010741 Conjunctivitis Diseases 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000004905 finger nail Anatomy 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 201000004946 genital herpes Diseases 0.000 description 4
- 229940074928 isopropyl myristate Drugs 0.000 description 4
- 229940051866 mouthwash Drugs 0.000 description 4
- 208000028169 periodontal disease Diseases 0.000 description 4
- 206010039083 rhinitis Diseases 0.000 description 4
- 229940012831 stearyl alcohol Drugs 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000009121 systemic therapy Methods 0.000 description 4
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 4
- 201000004647 tinea pedis Diseases 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 3
- 208000001688 Herpes Genitalis Diseases 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 241000893966 Trichophyton verrucosum Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 239000000668 oral spray Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 241000606750 Actinobacillus Species 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000223205 Coccidioides immitis Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 201000007336 Cryptococcosis Diseases 0.000 description 2
- 241000221204 Cryptococcus neoformans Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- 241001135221 Prevotella intermedia Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 241000223238 Trichophyton Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 229960003328 benzoyl peroxide Drugs 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 210000004904 fingernail bed Anatomy 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 229960003128 mupirocin Drugs 0.000 description 2
- 229930187697 mupirocin Natural products 0.000 description 2
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229940041678 oral spray Drugs 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000024 polymyxin B Polymers 0.000 description 2
- 229960005266 polymyxin b Drugs 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 1
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 1
- 241000884007 Arachnomyces nodosetosus Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 206010005098 Blastomycosis Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 206010051548 Burn infection Diseases 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241001480036 Epidermophyton floccosum Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 241000223221 Fusarium oxysporum Species 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 1
- 241001480000 Microsporum audouinii Species 0.000 description 1
- 241000893980 Microsporum canis Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241001547451 Neoscytalidium dimidiatum Species 0.000 description 1
- 241000807025 Nilus Species 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 241001537205 Paracoccidioides Species 0.000 description 1
- 206010033767 Paracoccidioides infections Diseases 0.000 description 1
- 201000000301 Paracoccidioidomycosis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 208000004364 Rhinosporidiosis Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000825258 Scopulariopsis brevicaulis Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 241001149963 Sporothrix schenckii Species 0.000 description 1
- 206010041736 Sporotrichosis Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 241001480048 Trichophyton tonsurans Species 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 206010061418 Zygomycosis Diseases 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229940089474 lamisil Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000006506 lobomycosis Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 201000007524 mucormycosis Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940041672 oral gel Drugs 0.000 description 1
- 201000009838 otomycosis Diseases 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 229940100613 topical solution Drugs 0.000 description 1
- 210000005010 torso Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95205907P | 2007-07-26 | 2007-07-26 | |
| US60/952,059 | 2007-07-26 | ||
| PCT/US2008/071350 WO2009015385A1 (en) | 2007-07-26 | 2008-07-28 | Antimicrobial peptide, compositions , and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013222846A Division JP5965884B2 (ja) | 2007-07-26 | 2013-10-28 | 抗菌ペプチド、組成物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010534684A JP2010534684A (ja) | 2010-11-11 |
| JP2010534684A5 JP2010534684A5 (enExample) | 2011-06-02 |
| JP5401457B2 true JP5401457B2 (ja) | 2014-01-29 |
Family
ID=40281862
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518431A Expired - Fee Related JP5401457B2 (ja) | 2007-07-26 | 2008-07-28 | 抗菌ペプチド、組成物及びその使用方法 |
| JP2013222846A Expired - Fee Related JP5965884B2 (ja) | 2007-07-26 | 2013-10-28 | 抗菌ペプチド、組成物及びその使用方法 |
| JP2016132290A Pending JP2017002057A (ja) | 2007-07-26 | 2016-07-04 | 抗菌ペプチド、組成物及びその使用方法 |
| JP2018153719A Active JP6722241B2 (ja) | 2007-07-26 | 2018-08-17 | 抗菌ペプチド、組成物及びその使用方法 |
| JP2020105975A Pending JP2020169190A (ja) | 2007-07-26 | 2020-06-19 | 抗菌ペプチド、組成物及びその使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013222846A Expired - Fee Related JP5965884B2 (ja) | 2007-07-26 | 2013-10-28 | 抗菌ペプチド、組成物及びその使用方法 |
| JP2016132290A Pending JP2017002057A (ja) | 2007-07-26 | 2016-07-04 | 抗菌ペプチド、組成物及びその使用方法 |
| JP2018153719A Active JP6722241B2 (ja) | 2007-07-26 | 2018-08-17 | 抗菌ペプチド、組成物及びその使用方法 |
| JP2020105975A Pending JP2020169190A (ja) | 2007-07-26 | 2020-06-19 | 抗菌ペプチド、組成物及びその使用方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8623811B2 (enExample) |
| EP (3) | EP2178549B1 (enExample) |
| JP (5) | JP5401457B2 (enExample) |
| KR (4) | KR101717275B1 (enExample) |
| CN (2) | CN102872447B (enExample) |
| AU (1) | AU2008278593B2 (enExample) |
| BR (3) | BR122019000266B1 (enExample) |
| CA (1) | CA2694046C (enExample) |
| CO (1) | CO6260098A2 (enExample) |
| CR (1) | CR11239A (enExample) |
| CY (2) | CY1118503T1 (enExample) |
| DK (2) | DK2178549T3 (enExample) |
| ES (2) | ES2609914T3 (enExample) |
| HR (1) | HRP20161722T1 (enExample) |
| HU (1) | HUE031136T2 (enExample) |
| IL (3) | IL203173A (enExample) |
| LT (1) | LT2178549T (enExample) |
| MX (1) | MX2010000916A (enExample) |
| NZ (1) | NZ582459A (enExample) |
| PL (1) | PL2178549T3 (enExample) |
| PT (2) | PT2178549T (enExample) |
| SG (1) | SG188128A1 (enExample) |
| SI (1) | SI2178549T1 (enExample) |
| WO (1) | WO2009015385A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014076993A (ja) * | 2007-07-26 | 2014-05-01 | Revance Therapeutics Inc | 抗菌ペプチド、組成物及びその使用方法 |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ598159A (en) * | 2006-12-29 | 2013-08-30 | Revance Therapeutics Inc | Transport molecules using reverse sequence hiv-tat polypeptides |
| US8080518B2 (en) * | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| MY155049A (en) | 2008-03-14 | 2015-08-28 | Allergan Inc | Immuno-based botolinum toxin serotype a activity assay |
| LT2379104T (lt) * | 2008-12-31 | 2018-04-10 | Revance Therapeutics, Inc. | Injekcinės botulino toksino vaisto formos |
| MX2011010335A (es) * | 2009-04-01 | 2012-01-12 | Revance Therapeutics Inc | Metodos y composiciones para tratar afecciones de la piel asociadas con hiperreactividad vascular. |
| PT2440231T (pt) | 2009-06-10 | 2020-01-08 | Nono Inc | Co-administração de um agente ligado a um peptido de internalização tat com um inibidor de desgranulação de mastócitos |
| CN102869373B (zh) * | 2009-06-25 | 2017-05-10 | 雷文斯治疗公司 | 不含白蛋白的肉毒杆菌毒素制剂 |
| US10022083B2 (en) | 2011-06-02 | 2018-07-17 | Abdulmohsen E. A. H. Al-Terki | Multiple oral and nasal surgical procedures method and kit |
| US8387798B1 (en) | 2012-04-27 | 2013-03-05 | Abdulmohsen E. A. H. Al-Terki | Mutiple oral and nasal surgical procedures method and kit |
| FR2997304B1 (fr) | 2012-10-26 | 2017-07-07 | Isp Investments Inc | Utilisation d’un extrait de lin, en tant qu’agent actif activateur de la synthese de peptides antimicrobiens |
| WO2014066916A2 (en) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
| US20140242110A1 (en) * | 2013-02-28 | 2014-08-28 | Dt Scimed, Llc | Dose, localization, and formulation of botulinum toxins in skin and muscle |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US11684567B2 (en) | 2015-08-05 | 2023-06-27 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US11793783B2 (en) | 2015-08-05 | 2023-10-24 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US11446236B2 (en) | 2015-08-05 | 2022-09-20 | Cmpd Licensing, Llc | Topical antimicrobial compositions and methods of formulating the same |
| ES2934714T3 (es) * | 2015-09-17 | 2023-02-24 | Contrafect Corp | Polipéptidos de lisina activos contra bacterias Gram-negativas |
| US10105381B2 (en) * | 2016-05-23 | 2018-10-23 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
| US10144767B2 (en) * | 2016-08-18 | 2018-12-04 | Board Of Regents Of The University Of Nebraska | Anti-microbial peptides and coatings |
| EP3541358A1 (en) * | 2016-11-21 | 2019-09-25 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| EP3675900A4 (en) | 2017-08-28 | 2021-05-05 | Revance Therapeutics, Inc. | Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders |
| CN107556374B (zh) * | 2017-08-30 | 2020-02-07 | 四川大学 | 唾液富脯蛋白仿生防龋功能多肽、其衍生物和盐及其应用 |
| CN107353334B (zh) * | 2017-08-30 | 2020-02-07 | 四川大学 | 基于唾液富酪蛋白的仿生防龋多肽、其衍生物和盐及应用 |
| JP7266202B2 (ja) * | 2018-02-19 | 2023-04-28 | 株式会社ファンケル | 化粧料及び抗炎症剤 |
| WO2020056191A1 (en) | 2018-09-13 | 2020-03-19 | Eirion Therapeutics, Inc. | Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors |
| WO2021207164A1 (en) * | 2020-04-08 | 2021-10-14 | Amicrobe, Inc. | Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections |
| CA3191359A1 (en) * | 2020-09-08 | 2022-03-17 | John D. O'neill | Tissue-derived matrikine compositions and methods therefor |
| CN122535420A (zh) | 2023-09-15 | 2026-08-07 | 雷文斯治疗公司 | 用于颈部肌张力障碍的使用肉毒毒素的系列治疗 |
| CN122514358A (zh) | 2023-09-19 | 2026-08-04 | 雷文斯治疗公司 | 需要快速起效美容效果和更平滑皮肤外观的患者中的使用肉毒毒素的治疗 |
| WO2025072381A1 (en) | 2023-09-25 | 2025-04-03 | Revance Therapeutics, Inc. | Methods for determining influence of carrier peptide on the binding of a therapeutic protein to a cell membrane |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
| US5670617A (en) * | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| JPH08501060A (ja) * | 1992-04-23 | 1996-02-06 | アレリックス バイオファーマスーティカルス インコーポレーテッド | ヘルペスウィルス感染症の治療 |
| EP0903408A3 (en) | 1992-08-21 | 2005-11-02 | Biogen, Inc. | Tat-derived transport polypeptide |
| CA2152373C (en) * | 1993-10-22 | 1998-12-15 | Michael Twist (Deceased) | Treatment of cytomegalovirus infection |
| DE69434535T2 (de) | 1993-12-28 | 2006-07-20 | Allergan, Inc., Irvine | Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen |
| US6232295B1 (en) | 1994-10-12 | 2001-05-15 | Jon Faiz Kayyem | Cell-specific contrast agent and gene delivery vehicles |
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| DE69637731D1 (de) * | 1995-08-23 | 2008-12-11 | Univ British Columbia | Antimikrobielle kationische peptide und methoden zu ihrer identifizierung |
| US6043218A (en) * | 1996-10-22 | 2000-03-28 | Medical University Of South Carolina | Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides |
| GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
| CA2314267A1 (en) * | 1997-12-10 | 1999-06-17 | Washington University | Anti-pathogen system and methods of use thereof |
| CA2309555A1 (en) * | 1997-12-12 | 1999-06-24 | Adam Sampson-Johannes | Selective killing and diagnosis of p53+ neoplastic cells |
| CA2347828A1 (en) | 1998-10-27 | 2000-05-04 | Mayo Foundation For Medical Education And Research | Methods for enhancing wound healing |
| EP1137664A2 (en) | 1998-12-10 | 2001-10-04 | Washington University | Protein transduction system and methods of use thereof |
| CZ20012038A3 (cs) | 1998-12-23 | 2001-09-12 | Idea Ag | Zdokonalený přípravek pro topické, neinvazivní použití in vivo |
| US7056656B1 (en) * | 1999-01-25 | 2006-06-06 | University Of Medicine And Dentistry Of New Jersey | Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA |
| US20030236214A1 (en) * | 1999-06-09 | 2003-12-25 | Wolff Jon A. | Charge reversal of polyion complexes and treatment of peripheral occlusive disease |
| US7008924B1 (en) * | 1999-07-21 | 2006-03-07 | Amgen, Inc. | VGF fusion polypeptides |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| US6544548B1 (en) * | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
| US6844324B1 (en) * | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
| US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| US6670322B2 (en) * | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
| US20030215412A1 (en) * | 2000-07-21 | 2003-11-20 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
| US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
| DK1301213T3 (en) | 2000-07-21 | 2017-03-27 | Revance Therapeutics Inc | MULTI-COMPONENT SYSTEMS FOR BIOLOGICAL TRANSPORT |
| US6696038B1 (en) * | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
| US20020127247A1 (en) * | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
| DE60233137D1 (de) | 2001-02-16 | 2009-09-10 | Univ R | Transporter mit beabstandeten arginin-teilchen |
| CA2446458A1 (en) * | 2001-05-09 | 2002-11-14 | Yale University | Toll/interleukin-1 receptor adaptor protein (tirap) |
| US7060498B1 (en) * | 2001-11-28 | 2006-06-13 | Genta Salus Llc | Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| MXPA04005611A (es) * | 2001-12-11 | 2005-04-19 | Cellgate Inc | Reactivos y conjugados de transporte de guanidinio. |
| AU2003216389A1 (en) | 2002-02-21 | 2003-09-09 | Essentia Biosystems, Inc. | Induction of hair growth with vascular endothelial growth factor |
| US20030215395A1 (en) * | 2002-05-14 | 2003-11-20 | Lei Yu | Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
| US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| JP4154218B2 (ja) * | 2002-11-27 | 2008-09-24 | 寛紀 高麗 | 新規抗菌性ポリペプチドとその利用 |
| US20060115480A1 (en) * | 2002-12-19 | 2006-06-01 | Yitzchak Hillman | Disease treatment via antimicrobial peptide inhibitors |
| IL153557A0 (en) * | 2002-12-19 | 2003-07-06 | Yitzchak Hillman | Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases |
| KR20050118669A (ko) * | 2003-02-01 | 2005-12-19 | 뉴랄랩 리미티드 | 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화 |
| WO2004084805A2 (en) * | 2003-03-19 | 2004-10-07 | The J. David Gladstone Institutes | Acetylated tat polypeptides and methods of use thereof |
| US7125842B2 (en) * | 2003-04-07 | 2006-10-24 | Canbas Co. Ltd. | Anti-fungal compounds and methods of use |
| MXPA06002828A (es) * | 2003-09-12 | 2006-06-23 | Univ British Columbia | Efectores de determinacion de inmunidad innata. |
| JP2005120050A (ja) * | 2003-10-20 | 2005-05-12 | Toagosei Co Ltd | 新規抗菌性ペプチドとその利用 |
| BRPI0508440A (pt) * | 2004-03-03 | 2007-07-24 | Revance Therapeutics Inc | composições e métodos para diagnóstico tópico e transporte terapêutico |
| HUE025656T2 (en) * | 2004-03-03 | 2016-04-28 | Revance Therapeutics Inc | Topical application and transdermal delivery of botulinum toxins |
| DK1927597T3 (en) * | 2004-08-18 | 2017-02-13 | Novabiotics Ltd | ANTIBACTERIAL PEPTIDES |
| EP1656951A1 (en) * | 2004-11-12 | 2006-05-17 | Xigen S.A. | Conjugates with enhanced cell uptake activity |
| EP2116603A3 (en) | 2004-11-12 | 2010-02-17 | The University Of British Columbia | Antimicrobial peptides |
| EP1661912A1 (en) | 2004-11-29 | 2006-05-31 | Xigen S.A. | Fusion protein comprising a BH3-domain of a BH3-only protein |
| JP4730584B2 (ja) * | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
| JP2006238751A (ja) * | 2005-03-02 | 2006-09-14 | Toagosei Co Ltd | ベロ毒素結合性を有する抗菌ペプチド及びその利用 |
| ES2362301T3 (es) | 2005-03-03 | 2011-07-01 | Revance Therapeutics, Inc. | Composiciones y procedimientos para aplicaciones tópicas y liberación transdérmica de un oligopéptido. |
| KR20070110402A (ko) | 2005-03-03 | 2007-11-16 | 레반스 테라퓨틱스 | 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법 |
| WO2006105450A2 (en) | 2005-03-30 | 2006-10-05 | Revance Therapeutics, Inc. | Compositions and methods for treating acne |
| WO2007059528A2 (en) | 2005-11-17 | 2007-05-24 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins |
| WO2008082889A2 (en) | 2006-12-29 | 2008-07-10 | Revance Therapeutics, Inc. | Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat |
| NZ598159A (en) | 2006-12-29 | 2013-08-30 | Revance Therapeutics Inc | Transport molecules using reverse sequence hiv-tat polypeptides |
| DK2178549T3 (en) * | 2007-07-26 | 2017-01-09 | Revance Therapeutics Inc | Antimicrobial peptide AND COMPOSITIONS THEREOF |
| LT2379104T (lt) * | 2008-12-31 | 2018-04-10 | Revance Therapeutics, Inc. | Injekcinės botulino toksino vaisto formos |
-
2008
- 2008-07-28 DK DK08826608.5T patent/DK2178549T3/en active
- 2008-07-28 SI SI200831732T patent/SI2178549T1/sl unknown
- 2008-07-28 CA CA2694046A patent/CA2694046C/en active Active
- 2008-07-28 EP EP08826608.5A patent/EP2178549B1/en active Active
- 2008-07-28 PT PT88266085T patent/PT2178549T/pt unknown
- 2008-07-28 BR BR122019000266-5A patent/BR122019000266B1/pt active IP Right Grant
- 2008-07-28 KR KR1020157019647A patent/KR101717275B1/ko active Active
- 2008-07-28 NZ NZ582459A patent/NZ582459A/en unknown
- 2008-07-28 KR KR1020107003133A patent/KR101722038B1/ko active Active
- 2008-07-28 KR KR1020187007958A patent/KR102088949B1/ko active Active
- 2008-07-28 SG SG2013009832A patent/SG188128A1/en unknown
- 2008-07-28 PT PT161840947T patent/PT3120862T/pt unknown
- 2008-07-28 US US12/669,705 patent/US8623811B2/en active Active
- 2008-07-28 BR BRPI0813627-0A patent/BRPI0813627B1/pt active IP Right Grant
- 2008-07-28 EP EP20166266.5A patent/EP3741380A1/en active Pending
- 2008-07-28 PL PL08826608T patent/PL2178549T3/pl unknown
- 2008-07-28 ES ES08826608.5T patent/ES2609914T3/es active Active
- 2008-07-28 HU HUE08826608A patent/HUE031136T2/en unknown
- 2008-07-28 HR HRP20161722TT patent/HRP20161722T1/hr unknown
- 2008-07-28 ES ES16184094T patent/ES2805225T3/es active Active
- 2008-07-28 EP EP16184094.7A patent/EP3120862B1/en active Active
- 2008-07-28 WO PCT/US2008/071350 patent/WO2009015385A1/en not_active Ceased
- 2008-07-28 DK DK16184094.7T patent/DK3120862T3/da active
- 2008-07-28 JP JP2010518431A patent/JP5401457B2/ja not_active Expired - Fee Related
- 2008-07-28 CN CN201210375756.5A patent/CN102872447B/zh active Active
- 2008-07-28 MX MX2010000916A patent/MX2010000916A/es active IP Right Grant
- 2008-07-28 CN CN200880100641.7A patent/CN101842107B/zh active Active
- 2008-07-28 AU AU2008278593A patent/AU2008278593B2/en active Active
- 2008-07-28 BR BR122019000258-4A patent/BR122019000258B1/pt active IP Right Grant
- 2008-07-28 LT LTEP08826608.5T patent/LT2178549T/lt unknown
- 2008-07-28 KR KR1020177002763A patent/KR20170016031A/ko not_active Ceased
-
2010
- 2010-01-06 IL IL203173A patent/IL203173A/en active IP Right Grant
- 2010-01-27 CR CR11239A patent/CR11239A/es not_active Application Discontinuation
- 2010-02-26 CO CO10023449A patent/CO6260098A2/es not_active Application Discontinuation
-
2012
- 2012-12-20 IL IL223784A patent/IL223784A/en active IP Right Grant
- 2012-12-20 IL IL223785A patent/IL223785A/en active IP Right Grant
-
2013
- 2013-10-28 JP JP2013222846A patent/JP5965884B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-04 JP JP2016132290A patent/JP2017002057A/ja active Pending
- 2016-12-14 CY CY20161101296T patent/CY1118503T1/el unknown
-
2018
- 2018-08-17 JP JP2018153719A patent/JP6722241B2/ja active Active
-
2020
- 2020-06-19 JP JP2020105975A patent/JP2020169190A/ja active Pending
- 2020-07-27 CY CY20201100692T patent/CY1123176T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014076993A (ja) * | 2007-07-26 | 2014-05-01 | Revance Therapeutics Inc | 抗菌ペプチド、組成物及びその使用方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6722241B2 (ja) | 抗菌ペプチド、組成物及びその使用方法 | |
| ES2729237T3 (es) | Lipopéptidos antimicrobianos cortos | |
| US9393261B2 (en) | Antimicrobial anti-chafing chelated silver oxide compound | |
| JP2015516943A (ja) | ポリペプチド及びその使用 | |
| CN104606085A (zh) | 一种新型高效抗菌的醋酸洗必泰纳米乳漱口液及其制备方法 | |
| HK40040748A (en) | Antimicrobial peptide and compositions thereof | |
| HK1180237B (en) | Antimicrobial peptide, compositions, and methods of use | |
| HK1147424B (en) | Antimicrobial peptide, compositions, and methods of use | |
| HK1147424A (en) | Antimicrobial peptide, compositions, and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110418 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110720 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130228 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130527 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130603 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130625 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130702 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130725 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130801 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130830 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130926 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131028 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5401457 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |